Evogene Stock Is Estimated To Be Significantly Overvalued
- By GF Value
The stock of Evogene (NAS:EVGN, 30-year Financials) shows every sign of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $4.37 per share and the market cap of $193.6 million, Evogene stock shows every sign of being significantly overvalued. GF Value for Evogene is shown in the chart below.
Because Evogene is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth.
Link: These companies may deliever higher future returns at reduced risk.
Since investing in companies with low financial strength could result in permanent capital loss, investors must carefully review a company's financial strength before deciding whether to buy shares. Looking at the cash-to-debt ratio and interest coverage can give a good initial perspective on the company's financial strength. Evogene has a cash-to-debt ratio of 19.77, which ranks in the middle range of the companies in Biotechnology industry. Based on this, GuruFocus ranks Evogene's financial strength as 5 out of 10, suggesting fair balance sheet. This is the debt and cash of Evogene over the past years:
Investing in profitable companies carries less risk, especially in companies that have demonstrated consistent profitability over the long term. Typically, a company with high profit margins offers better performance potential than a company with low profit margins. Evogene has been profitable 1 years over the past 10 years. During the past 12 months, the company had revenues of $1 million and loss of $0.82 a share. Its operating margin of -2385.96% worse than 82% of the companies in Biotechnology industry. Overall, GuruFocus ranks Evogene's profitability as poor. This is the revenue and net income of Evogene over the past years:
Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term performance of a company's stock. The faster a company is growing, the more likely it is to be creating value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth rate of Evogene is -34.6%, which ranks worse than 76% of the companies in Biotechnology industry. The 3-year average EBITDA growth rate is -4.2%, which ranks in the middle range of the companies in Biotechnology industry.
Another way to evaluate a company's profitability is to compare its return on invested capital (ROIC) to its weighted cost of capital (WACC). Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the ROIC is higher than the WACC, it indicates that the company is creating value for shareholders. Over the past 12 months, Evogene's ROIC was -106.86, while its WACC came in at 7.00. The historical ROIC vs WACC comparison of Evogene is shown below:
In conclusion, Evogene (NAS:EVGN, 30-year Financials) stock gives every indication of being significantly overvalued. The company's financial condition is fair and its profitability is poor. Its growth ranks in the middle range of the companies in Biotechnology industry. To learn more about Evogene stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
This article first appeared on GuruFocus.